EQT Private Equity agreed to acquire Qiagen for €10.8 billion (about $12.1B) in cash, taking the life-sciences tools and diagnostics provider private. The boards said the deal offers the best path for the company’s next growth phase, citing greater flexibility for longer-term investment. The transaction follows years of takeover interest and scrutiny, including a January review process reported earlier in the market. Investors responded positively to the announcement, with Qiagen shares moving sharply as terms were laid out and a structured premium above prior trading levels was referenced. Qiagen will remain under the existing brand until the takeover offer closes, with the deal contingent on shareholder support and post-closing measures. The move sets up a new ownership structure for instrument and workflow companies at a time when diagnostics and research tools remain strategic for translational pipelines.